Overall, the data indicate that cancer patients, especially those with B-cell lymphoma and certain solid tumors, have elevated TK1 and CRP levels compared to healthy controls, highlighting differences in inflammatory and tumor marker levels across these groups. This evidence concerns the gene TK1 and B-cell non-Hodgkin lymphoma.